Open AccessS772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
Author(s) -
Peter Bossuyt,
Marc Ferrante,
Filip Baert,
Silvio Danese,
Brian G. Feagan,
Edward V. Loftus,
Julián Panés,
Laurent PeyrinBiroulet,
Zhihua Ran,
Alessandro Armuzzi,
G D’Haens,
Alexandra Song,
Ezequiel Neimark,
Xiaomei Liao,
Qian Zhou,
Sofie Berg,
Kori Wallace,
Remo Panaccione
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776620.39225.48
Subject(s) - medicine , placebo , crohn's disease , gastroenterology , population , endoscopy , colonoscopy , clinical endpoint , clinical trial , randomized controlled trial , disease , surgery , pathology , colorectal cancer , alternative medicine , environmental health , cancer